FDA grants orphan-drug review status to Biogen leukemia drug

02/7/2007 | San Diego Union-Tribune

The FDA granted Biogen Idec orphan-drug status and accelerated review of its leukemia drug, lumiliximab, for treating the relatively rare chronic lymphocytic leukemia. The drug is in a Phase III trial comparing its use in combination with chemotherapy and the firm's Rituxan against just the combination of Rituxan and chemotherapy.

View Full Article in:

San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC